Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

(RTTNews) - Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological ...

Shilajit, a natural substance, has been utilized in traditional Ayurvedic medicine for multiple centuries. This substance, discovered in the Himalayas, is the result of the decomposition of plants ...

Only Netflix, with a market cap of $295 billion, is higher. Wall Street analysts believe the DIS stock price could rise almost 16% to $112.13 over the coming year. Full-year earnings per share growth ...

Sol De Janeiro skincare and fragrance products will soon return to Dis-Chem shelves, with the pharmaceutical retailer confirming it is negotiating directly with the popular US brand. Speaking after ...

South Africans need to be in the know if we want to create a prosperous future. News24 has kept the country informed for 25 years, and we're about to enter a new chapter of fearless journalism. Join ...

JOHANNESBURG, Oct 25 (Reuters) - South African pharmacy group Dis-Chem Pharmacies (DCPJ.J), opens new tab said at its conference call on Friday it will launch its insurance business, Dis-Chem Life ...

South African pharmacy group Dis-Chem reported a 16.3% jump in headline earnings for the six months ended 31 August 2024, it announced on Sens on Friday. Dis-Chem also posted a 16.1% surge in its ...

Dis-Chem, South Africa's leading health and beauty retailer, is proud to present the World of Beauty event, a celebration of beauty, new and exceptional products. According to Statista ...

Dis-Chem has upped its dividend amidst higher profits, with the group hoping to add 30,000 sqm of new retail space in the medium term and start operating as a life insurer early next year.

Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. With a market cap of $26.6 bi ...